including global rating of distress, medication assessment, and Index of Premature Ejaculation (IPE). Wilcoxon rank-sum test was used for comparison of all outcomes.
INTRODUCTION AND OBJECTIVES:
To compare the improvement of erectile dysfunction (ED) as well as safety of mirodenalfil 50mg once daily and 100mg on-demand in patients with radical prostatectomy due to prostate cancer.
METHODS: Prospective study was done with 166 patients who had ED after taken radical prostatectomy due to prostate cancer from June 2013 to October 2014. Out of 184 individuals, 171 met inclusion criteria and 153 finished the research. Patients were divided into two groups. Group 1 had mirodenafil 50mg daily and Group 2 had mirodenafil 100mg on-demand. The ?ve-item version of the International Index of Erectile Function (IIEF-5), SEP Q2, Q3 were assessed immediately before initiation of treatment (V1) and after two (V2), six (V3) and twelve months of treatment (V4). Also, to investigate the safety, blood pressure, pulse, and side effect were evaluated.
RESULTS: Out of 171 individuals, 153 (89.4%) finished the research (group 1: n¼74, 48.4%, group 2: n¼79, 51.6%). Statistically, there were no difference of IIEF-5 at V1 between two groups. Both groups had meaningful improvement on IIEF-5 in V2,V3, V4 and group 1 had better improvement than group 2 (10.9AE4.1 vs. 8.0AE5.3, D4.0AE2.6, p¼0.01) (Table1). Group 1 had larger improvements than Group 2 in SEP Q2 and Q3 significantly (V4-Q2: 60.1% vs. 50.7%, p¼0.01, Q3: 58.4% vs.48.8%, p¼0.01). There was no drop out patients due to cardiovascular problems and other side effects.
CONCLUSIONS: The administration of a 5 mg dose of mirodenafil daily to patients who had erectile dysfunction that had undergone a radical prostatectomy due to prostate cancer had batter effect on the recovery and maintenance of erectile function than 100mg dose of mirodenafil. The side effects were insignificant for both dosing schedules. METHODS: A multi-center, double-blind, randomized shamcontrolled clinical trial was conducted. 70 patients (46 cases for LI-ESWT treatment group and 24 cases for the placebo group) at age 20-70 years, who had mild or moderate Vasculogenic ED evaluated with the International Index of Erectile Function erectile function domain (IIEF-EF) were recruited for this study. Screening, treatment and results were performed in sequence. 4 weekly sessions for the treatment stage: A total of 5000 shockwaves were applied for each treatment and 4 areas were conducted including: 900 shockwaves in right and left crura, and 1600 shockwaves in each site. Effectiveness was assessed according to the International Index of Erectile Function erectile function domain (IIEF-EF), questions 2 and 3 of the Sexual Encounter Profile (SEP), Global Assessment Question (GAQ) scores, and Erection Hardness Scale (EHS) at baseline and at 1 and 3 months after treatment. The study was approved by Peking University First Hospital ethics committee, and all patients signed an informed consent form.
Source of Funding: SK chemicals Korea
RESULTS: For Full Analysis Set (FAS) and Per-Protocol Set (PPS), the average IIEF-EF increased significantly from 18.04AE3.94 (17.90AE3.77) at baseline to 22.02AE4.13 (21.95AE4.06) at 1 months post treatment, and was 22.54AE3.98 (22.49AE3.90) at the 3 months follow-up. The success rate by LI-ESWT is 67.39% (73.17%) after 1months post treatment VS 20.83% (23.81%) in the placebo group and is 69.57% (73.17%) after 3 months post treatment VS 20.83% (23.81%) in the placebo group by FAS (PPS). SEP, GAQ, EHS analysis were also significantly improved compared to the placebo controls (p<0.05). No side effects were reported in this study. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1345
